Myriad Genetics Overview
Myriad Genetics Target Price
Analysts' 12-month price predictions for MYGN.
Share Price
$6.61
Average Target Price
$10.33
56.3% upside
56.3% upside3 analysts in the last 4 months
High: $18 | Low: $6
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-05-07 | Craig-HallumBill Bonello | $18 | 172.3% upside |  |
| 2025-05-07 | UBSLu Li | $7 | 5.9% upside | |
| 2025-05-07 | Wells FargoBrandon Couillard | $6 |  9.2% downside | |
| 2025-03-12 | Piper Sandler | $12.5 | 89.1% upside | |
| 2025-03-04 | Piper Sandler | $11.5 | 74% upside | |
| 2024-12-09 | Leerink PartnersPuneet Souda | $21 | 217.7% upside | |
| 2024-10-14 | ScotiabankSung Ji Nam | $34 | 414.4% upside | |
| 2024-09-19 | Morgan StanleyTejas Savant | $32 | 384.1% upside | |
| 2024-08-27 | Wells FargoBrandon Couillard | $35 | 429.5% upside | |
| 2024-08-07 | GuggenheimSubbu Nambi | $29 | 338.7% upside | |
| 2024-06-26 | ScotiabankSung Ji Nam | $29 | 338.7% upside | |
| 2024-05-13 | Piper SandlerJon Peterson | $28 | 323.6% upside | |
| 2023-12-21 | Piper SandlerDavid Westenberg | $23 | 248% upside | |
| 2022-10-05 | StephensMason Carrico | $22 | 232.8% upside | |
| 2022-04-19 | Goldman Sachs | $23 | 248% upside | |